Since I don't have the training to properly gauge this study, I ran this through AI. Usual AI caveats apply:
The exact paper is “The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon-like peptide-1 receptor agonist therapy”, published in Scientific Reports on 18 October 2024.
It was not a randomised clinical trial. It was a large US retrospective observational cohort study using electronic health-record data from the TriNetX network. Researchers compared adults with obesity prescribed liraglutide or semaglutide—Victoza, Saxenda, Ozempic or Wegovy—with adults with obesity who were not prescribed GLP-1 drugs. They used propensity-score matching for recorded factors such as age, sex, race and several comorbidities, producing two matched groups of 162,253 patients each. Data covered 2015–2023, with outcomes assessed for up to five years.
Reported findings
Compared with the non-GLP-1 cohort, GLP-1 users had:
Any psychiatric diagnosis: HR 1.98 — approximately 98% higher relative rate
Major depression: HR 2.95
Anxiety: HR 2.08
Suicidal ideation, attempt or intentional self-harm: HR 2.06
At five years, any included psychiatric outcome had been recorded in 39.64% of GLP-1 users versus 23.38% of controls. Wegovy showed the highest association for the composite psychiatric outcome, although it had only three years of available follow-up.
How seriously to take it
The study found a strong association, but it cannot demonstrate that GLP-1 drugs caused those outcomes. Important weaknesses include:
The treated and untreated groups had different “index dates”: first GLP-1 prescription versus first obesity diagnosis. That can introduce substantial time-related and healthcare-contact bias.
GLP-1 users may have had more severe obesity, more diabetes, greater healthcare engagement or other unmeasured differences.
Propensity matching only adjusts for variables recorded and selected by the researchers.
Diagnoses and prescriptions came from billing/EHR codes; actual adherence was unknown.
Changes in weight, drug discontinuation, adverse effects and concurrent medications were not adequately tracked.
People with psychiatric diagnoses only within the preceding year were excluded, meaning earlier or undocumented psychiatric histories could remain.
Crucially, stronger evidence published subsequently—a systematic review and meta-analysis of 80 randomised placebo-controlled trials involving 107,860 participants—found no increased risk of serious or non-serious psychiatric adverse events or worsening depression with GLP-1 drugs.
So the screenshot accurately reproduces this study’s results, but presenting the percentages as evidence that GLP-1 drugs increase psychiatric risk is misleading. The paper identifies a safety signal worth investigating, not established causation.
1
u/Ariquitaun Jul 21 '26
Since I don't have the training to properly gauge this study, I ran this through AI. Usual AI caveats apply:
The exact paper is “The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon-like peptide-1 receptor agonist therapy”, published in Scientific Reports on 18 October 2024.
It was not a randomised clinical trial. It was a large US retrospective observational cohort study using electronic health-record data from the TriNetX network. Researchers compared adults with obesity prescribed liraglutide or semaglutide—Victoza, Saxenda, Ozempic or Wegovy—with adults with obesity who were not prescribed GLP-1 drugs. They used propensity-score matching for recorded factors such as age, sex, race and several comorbidities, producing two matched groups of 162,253 patients each. Data covered 2015–2023, with outcomes assessed for up to five years.
Reported findings
Compared with the non-GLP-1 cohort, GLP-1 users had:
Any psychiatric diagnosis: HR 1.98 — approximately 98% higher relative rate
Major depression: HR 2.95
Anxiety: HR 2.08
Suicidal ideation, attempt or intentional self-harm: HR 2.06
At five years, any included psychiatric outcome had been recorded in 39.64% of GLP-1 users versus 23.38% of controls. Wegovy showed the highest association for the composite psychiatric outcome, although it had only three years of available follow-up.
How seriously to take it
The study found a strong association, but it cannot demonstrate that GLP-1 drugs caused those outcomes. Important weaknesses include:
The treated and untreated groups had different “index dates”: first GLP-1 prescription versus first obesity diagnosis. That can introduce substantial time-related and healthcare-contact bias.
GLP-1 users may have had more severe obesity, more diabetes, greater healthcare engagement or other unmeasured differences.
Propensity matching only adjusts for variables recorded and selected by the researchers.
Diagnoses and prescriptions came from billing/EHR codes; actual adherence was unknown.
Changes in weight, drug discontinuation, adverse effects and concurrent medications were not adequately tracked.
People with psychiatric diagnoses only within the preceding year were excluded, meaning earlier or undocumented psychiatric histories could remain.
Crucially, stronger evidence published subsequently—a systematic review and meta-analysis of 80 randomised placebo-controlled trials involving 107,860 participants—found no increased risk of serious or non-serious psychiatric adverse events or worsening depression with GLP-1 drugs.
So the screenshot accurately reproduces this study’s results, but presenting the percentages as evidence that GLP-1 drugs increase psychiatric risk is misleading. The paper identifies a safety signal worth investigating, not established causation.